Opinion|Videos|July 23, 2024
Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC
A panel of experts describe the key challenges and unmet needs for patients with newly diagnosed mNSCLC.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Describe the key challenges and unmet needs for patients with newly diagnosed mNSCLC lacking targetable driver mutations.
- What proportion of mNSCLC patients harbor drivers like EGFR, ALK, etc?
- How does the presence of these mutations impact prognosis and guide first-line treatment?
- What are the unique challenges and unmet needs for specific subgroups of mNSCLC patients without drivers, such as those with without PD-L1 expression, squamous histology, or brain metastases?
- Beyond PD-L1, what factors do you consider when selecting first-line treatment in the driver-negative setting?
Advertisement
Related to this article
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
Advertisement
Advertisement
Trending on AJMC
1
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
2
Using Complement Inhibitors in GA Comes With Pros and Cons
3
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5